The Next Generation of ADCs and the Potential of ABBV-400 in Lung Cancer Treatment

Antibody-Drug Conjugates (ADCs) are at the forefront of cancer treatment, providing targeted therapies with promising results for lung cancer. In this exclusive interview, we spoke with Dr. Maria de Miguel, Medical Oncologist and Clinical Investigator at START Madrid, HM Sanchinarro Cancer Center, to discuss the latest advancements in ADC research and data presented at ESMO 2024.

Dr. de Miguel will analyze the future of ADCs in oncology and how these advancements could reshape personalized cancer treatment and improve outcomes for patients with solid tumors.

Some of the main topics in this interview include:

• Can you provide an overview of your research on telisotuzumab adizutecan (ABBV-400) and its potential as a c-Met directed antibody-drug conjugates (ADCs) for NSCLC? What makes it stand out compared to other ADCs in development?
• The confirmed overall response rate (ORR) for ABBV-400 in NSCLC was 43.8%, and the clinical benefit rate was 85.4%. Can you elaborate on how these results compare to other existing treatments for this patient group?
• What insights have you gained from the ongoing biomarker analyses exploring the association between c-Met protein expression and treatment response? How might these results guide future clinical decision-making?
• Could you discuss the most common treatment-emergent adverse events, particularly anemia and neutropenia, in patients treated with ABBV-400? How are these managed clinically to ensure patient safety while maintaining efficacy?
• With increasing interest in ADCs for solid tumors, what do you think are the key factors that will influence the future success of ADCs in oncology? Are there any specific hurdles you foresee for widespread clinical adoption.
• After presenting your findings at ESMO 2024, what key message would you like to convey to oncologists and researchers about the future of ADCs in lung cancer treatment and personalized oncology?